-
Product Insights
Meningitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Meningitis - Global Clinical Trials Review, 2025" provides an overview of Meningitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Meningitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Dilated Cardiomyopathy (DCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics. - In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. - Currently, 34 molecules are being developed for DCM across various stages of the pipeline. - Over the past 10...
-
Sector Analysis
Hypothyroidism (HT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypothyroidism Therapeutics. - In 2024, more than 300 million diagnosed prevalent cases of hypothyroidism are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The hypothyroidism market space is saturated with generic drugs, and thyroid-stimulating hormone agonists dominate the market. - The hypothyroidism pipeline holds seven molecules, with only one asset in Phase III development. - Over the past 10 years, the US has...
-
Sector Analysis
Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics. - In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms. - A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and...
-
Sector Analysis
Bladder Cancer Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. This report includes an assessment of the disease epidemiology and 10-year patient-based...
-
Thematic Analysis
South Korea Drug Development Trends - Strategic Intelligence
South Korea has become a significant player in the global pharmaceutical industry and drug development space, fueled by its advanced healthcare system, growing pharmaceutical sector, strong research infrastructure, and government-backed initiatives to support innovation. The country has been increasingly focusing on innovation and cutting-edge technologies, such as CGTs, as well as development of advanced therapies such as ADCs, mRNA-based treatments, and CAR-T therapies. As a result, South Korea is establishing itself as a growing hub for clinical trials and drug...
-
Sector Analysis
Major Depressive Disorder in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2029
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
-
Sector Analysis
Major Depressive Disorder in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2029
This report covers the 8 major markets and provides an Excel-based forecast model for the Major Depressive Disorder market through 2029.
-
Sector Analysis
Myelodysplastic Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase...
-
Sector Analysis
Polycystic Kidney Disease (PKD) and Autosomal Dominant Polycystic Kidney Disease (ADPKD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics. - GlobalData epidemiologists estimate that there were 1.19 million diagnosed prevalent cases of Polycystic Kidney Disease (PKD) & Autosomal Dominant Polycystic Kidney Disease (ADPKD) (PKD & ADPKD) infection in 2024, which is expected to increase slightly to 1,23 million diagnosed prevalent cases by 2029. - Currently, there is only one approved innovator therapy available...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.